核酸适配体识别-荧光法检测赭曲霉素A

建立了核酸适配体识别-荧光探针技术检测赭曲霉素A(OTA)的新方法.基于微孔板上固定的核酸适配子与目标物质OTA结合时构象发生变化,导致预先与其互补杂交的FAM标记短链DNA解离,引起荧光信号发生变化,据此可实现对OTA的定量检测.当微孔板包被亲和素浓度为25 mg/L、适配子浓度为50 nmol/L,FAM标记互补短...     

链亲和素-磁性微粒的制备及其应用

通过物理吸附和共价作用机制, 制备两种链亲和素-磁性微粒, 即链亲和素-金磁微粒和链亲和素-氨基磁粒, 并对其在不同缓冲液中的稳定性进行研究; 采用酶抑制法测定两种链亲和素-磁性微粒对游离生物素的结合能力; 分别以紫外吸收和固相核酸杂交方法, 测定两种链亲和素-磁性微粒对生物素标记寡核苷酸探针的固定化容量及活性, 并与Dynabeads®M-270 Streptavidin进行比较. 结果表明: 通过物理吸附作用制备的链亲和素-金磁微粒, 适用于核酸杂交与检测常用的STE (Tris-NaCl-EDTA) 缓冲系统, 通过共价作用形成的链亲和素-氨基磁粒, 适用于STE和磷酸盐(PBS)缓冲系统; 1 mg链亲和素-金磁微粒和链亲和素-氨基磁粒对游离生物素的最大结合容量分别为4950和5115 pmol; 对生物素标记寡核苷酸探针(24 mer) 的结合容量分别为2839和2978 pmol, 测定结果均是Dynabeads®M-270 Streptavidin的6~7倍; 与FITC-标记互补寡核苷酸的杂交结果表明, 固定于链亲和素-磁性微粒表面的寡核苷酸探针保持了较好的生物学活性.     

基于分子发夹/荧光微球的侧向层析法定量检测黄曲霉毒素B1

基于分子发夹/荧光微球探针构建了一种侧向层析定量检测黄曲霉毒素B1(AFB1)的新方法。一条含有AFB1适配体的分子发夹与荧光微球偶联后,形成的标记探针被喷涂在试纸条的结合垫上。一条5'端含有链霉亲和素的寡核苷酸序列包被在硝酸纤维素膜的检测线上,另一条包含有AFB1适配体互补链的寡核苷酸序列包被在硝酸纤维素膜的质控线上。当待测样本中含有AFB1时,AFB1先与标记物结合垫处标记探针中的AFB1适配体结合,同时,标记探针中的DNA分子发夹‘茎’的双链被打开,AFB1与标记探针形成的复合物层析到反应膜的检测区时,被检测区的寡核苷酸序列捕获,检测区出现亮线。利用该原理,通过一个"off-on"的光信号,实现了对AFB1的高灵敏检测。实验结果表明,AFB1在0.1~50μg/L质量浓度范围内,检测线处的荧光强度(T)和质控线荧光强度(C)的比值与AFB1质量浓度呈良好的线性关系,检出限(S/N=3)达0.05μg/L,且具有很高特异性,可实现对实际样品中AFB1的准确检测。     

基于双核酸适配体的夹心试纸条法在多菌灵检测中的应用研究

建立了一种胶体金标记核酸适配体的试纸条用于多菌灵的快速检测。将核酸适配体CZ13与AuNPs结合作为信号探针，生物素标记的核酸适配体CZ12固定在链霉亲和素包被膜上作为捕获探针。优化了影响灵敏度的实验条件，如信号探针制备中使用的NaCl和适配体的浓度，检测线上链霉亲和素与生物素标记的核酸适配体的摩尔比等。在最佳实验条件下，多菌灵检测范围为0.5～40μg/mL,检测限为0.45μg/mL。该方法可用于实际样品检测，检测时间为15 min,与果蔬中常见农残不存在交叉反应，方法准确、可靠、使用简便，适合样品的现场快速检测。     

基于核酸外切酶酶切反应的纳米金比色法检测T4多聚核苷酸激酶活性

建立了基于纳米金凝聚变色效应的检测T4多聚核苷酸激酶(T4 PNK)活性的方法。鉴于寡核苷酸链标记的纳米金能够稳定存在于一定浓度的盐离子缓冲溶液中,利用5’羟基修饰的发夹型探针作为金标探针,有T4 PNK存在时,金标探针5’羟基磷酸化,λ核酸外切酶被激活,酶切发夹型探针茎部双链DNA片段,接着在RecJf核酸外切酶作用下降解纳米金上修饰的残余的单链DNA,使得纳米金在一定盐离子浓度下团聚,溶液变成蓝紫色。结果表明,T4 PNK激酶检测的线性响应范围为0.5~4.0 U/mL,检测下限为0.24 U/mL。     

寡核苷酸在石英金膜表面的固定及其分析性能

将巯基修饰的寡核苷酸探针通过自组装技术固定于以光刻溅射技术制作的石英金片上来制备核酸传感器探头,然后将探头与生物素标记的21个碱基目标寡核苷酸杂交,再利用生物素－亲合素的作用联入亲合素标记的碱性磷酸酯酶,酶催化底物AMPPD发光来达到测定寡核苷酸的目的,测得杂交清洗温度70℃时探头对错配碱基核酸的选择性最佳,探头的测定范围为0．1－100μg/L,最低检测浓度为0．1μg/L,重复测定的相对标准偏差为11．3％。     

生物素-亲和素放大酶联免疫吸附法测定氯胺酮

建立了检测氯胺酮的生物素-亲和素放大酶联免疫吸附测定法(BA-ELISA)。实验最佳测定条件:抗原包被浓度为2.0mg/L、氯胺酮单克隆抗体浓度为10.2mg/L,生物素化羊抗小鼠IgG(Biotin-IgG)和酶标链霉亲和素(SA-HRP)的最佳反应浓度分别为0.29和1.0mg/L。在此优化条件下,方法的线性范围为0.1～1000μg/L;检出限为0.03μg/L。氯胺酮生物样品的加标回收率为94%～102%。与酶标二抗体系ELISA法相比,BA-ELISA具有更高的灵敏度,适于低浓度氯胺酮的检测。     

5,5'-二硫代双(琥珀酰亚氨基-2-硝基苯甲酸)功能化的SERS纳米探针在免疫检验中的应用

以5,5'-二硫代双(琥珀酰亚氨基-2-硝基苯甲酸)(DSNB)分子作为偶联剂将蛋白质结合在金纳米粒子表面,既保持了蛋白质的生物活性,同时DSNB分子又具有较高的表面增强拉曼散射(SERS)活性,可作为蛋白质定量分析的探针分子.选用生物素与亲和素的特异性识别以及抗原抗体的免疫识别2个生物反应体系,将SERS纳米探针固定在蛋白质检测芯片上.以硅片为蛋白质检测载体,利用硅片在520 cm-1处的拉曼特征峰为内标,对人Ig G抗体进行定量分析.结果表明,该探针对人Ig G抗体检测的最低浓度可以达到5 pg/m L.     

磁珠表面核酸探针的固定及电化学方法检测

报道了用戊二醛将氨基修饰的寡核苷酸探针固定于氨基磁珠表面制成核酸传感器，传感器与生物素标记的DNA杂交，再利用亲和素－生物素偶合系统，偶联上亲和素标记的碱性磷酸酶。碱性磷酸酶催化底物α-萘酚磷酸酯（α－NATP）水解形成具有电化学活性的α-萘酚，用示差脉冲伏安法测定杂交结果，本法测得短链DNA片断的浓度线性范围为10－1000μg/L；最低检测限为3μg/L。作者优化了相关的检测条件，并成功测定了乙型肝炎病毒HBV－DNA的片段。     

基于核酸适配子识别的荧光法检测可卡因

基于荧光标记和核酸适配子识别可卡因,建立了简单、灵敏的可卡因新型荧光分析法.在微孔板表面组装亲和素-生物素化可卡因适配子-FAM标记可卡因适配子互补短链复合物,根据加入可卡因前后荧光强度的变化来定量可卡因.实验考察了微孔板包被亲和素浓度、生物素标记适配子用量、FAM标记可卡因适配子互补短链用量、反应温度、反应时间等因素...     

Determination of acyclovir in horse plasma and body fluids by high-performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry

Two methods are presented for the determination of 'respectively' the plasma protein unbound and total concentration of acyclovir in horse plasma and body fluids: first, a liquid-liquid extraction was performed on plasma, combined with HPLC-fluorescence detection for the total plasma concentration; second a more sensitive method using high-performance liquid chromatography combined with heated electrospray ionization tandem mass spectrometry (LC-HESI-MS/MS) was described for plasma and for body fluids analysis. To obtain the unbound concentration of acyclovir in plasma, a simple deproteinization step using a Microcon filter was performed. Ganciclovir was used as an internal standard. Analysis was carried out on an Inertsil 5 ODS-3 column for the HPLC-fluorescence method. For the LC-HESI-MS/MS method a PLRP-S column was used. The limit of quantification (LOQ) for the total concentration was set at 50 and 2 ng mL(-1) for the HPLC-fluorescence method and the LC-HESI-MS/MS method, respectively. The limit of quantification for the unbound concentration was set at 5 ng mL(-1) and at 2 ng mL(-1) for body fluids. The methods were successfully used to perform pharmacokinetic and clinical studies in horses after intravenous and oral dosage of acyclovir and its prodrug valacyclovir.     

Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies

A liquid chromatography/mass spectrometry method, for rapid determination of five cytochrome P450 (CYP) probe drugs and their relevant metabolites in human plasma and urine, is described. The five specific probe substrates/metabolites, caffeine/paraxanthine (CYP1A2), tolbutamide/4-hydroxytolbutamide/carboxytolbutamide (CYP2C9), omeprazole/5-hydroxyomeprazole (CYP2C19), debrisoquine/5-hydroxydebrisoquine (CYP2D6) and midazolam/1'-hydroxymidazolam (CYP3A), together with the internal standards (phenacetin and paracetamol), in plasma and urine, were extracted using solid-phase extraction. The chromatography was performed using a C18 column with an isocratic mobile phase consisting of acetonitrile and 0.1% formic acid in water (70:30). The triple-quadrupole mass spectrometer was operated in both positive and negative modes, and multiple reaction monitoring was used for quantification. The method was validated over the concentration ranges 0.05-5 microg/mL for caffeine and paraxanthine, 0.02-2 microg/mL for tolbutamide, 0.1-20 microg/mL for 4-hydroxytolbutamide, carboxytolbutamide, debrisoquine and 5-hydroxydebrisoquine, 5-2500 ng/mL for omeprazole and 5-hydroxyomeprazole, and 1-100 ng/mL for midazolam and 1'-hydroxymidazolam. The intra- and inter-day precision were 0.3-13.7% and 1.9-14.3%, respectively, and the accuracy ranged from 93.5-107.2%. The lower limit of quantification varied between 1 and 100 ng/mL. The present method provides a robust, fast and sensitive analytical tool for the five-probe drug cocktail, and has been successfully applied to a clinical phenotyping study in 16 subjects.     

Immunoassay of serum alpha(1)-antitrypsin by affinity-probe capillary isoelectric focusing using a fluorescence-labeled recombinant antibody fragment

An immunoassay for human alpha(1)-antitrypsin based on affinity-probe capillary isoelectric focusing (AP-CIEF) is described. The method is based on the separation of free and bound labeled antibody fragments by CIEF with laser-induced fluorescence detection. A recombinant Fab' fragment of mouse immunoglobulin G1 (IgG1) against human alpha(1)-antitrypsin was labeled with tetramethylrhodamine on the single cysteine residue at the hinge region. A single pI isomer of the labeled Fab' was purified by IEF in a slab of agarose gel and was then used as the affinity probe for alpha(1)-antitrypsin. The use of recombinant Fab' considerably simplified the labeling process. Although there was some difficulty in the quantification of native alpha(1)-antitrypsin with the affinity probe, carbamylation of the antigen sample by heat treatment with urea made the complex peaks appear reproducibly and more distinct, thus facilitating the identification and quantification of the complex. The system provided an almost linear response to a pure sample of alpha(1)-antitrypsin over a concentration range of 5-1000 ng/mL and the detection limit extended down to around 2 ng/mL. Alpha(1)-antitrypsin in a serum sample was determined using this system to be 1.2 mg/mL which is comparable to the reported value for the protein.     

Quantification of a potent 5-HT2a antagonist and an active metabolite in rat plasma and brain microdialysate by liquid chromatography-tandem mass spectrometry

A method based on liquid chromatography-tandem mass spectrometry and microbore column separation was developed for the quantification of a potent 5-HT_2a receptor antagonist (R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)etnyl]-4-piperidine-methanol (I) and the desmethyl metabolite (II) in rat brain extracellular fluid (ECF) following microdialysis sampling. The analytical method was also applied to determining plasma concentrations of these compounds. The lower limit of quantification (LLQ) for each compound in microdialysis perfusate is 500 pg/mL, which translates to <7 fmol (injected). The recovery of I and II for the microdialysis probe in brain ECF was 18.5 and 22.7%, respectively. The LLQ for each compound in plasma is 1 ng/mL. The inherent selectivity offered by tandem mass spectrometry eliminated chemical noise, thereby improving the detectability of these compounds. These methods were used to confirm that I and II penetrated the blood-brain barrier following administration of I to rats and enabled comparison of plasma and brain ECF concentrations.     

Cytosine-phosphodiester-guanine oligodeoxynucleotide (CpG ODN)-capped hollow mesoporous silica particles for enzyme-triggered drug delivery

We designed, for the first time, an enzyme-triggered drug delivery system that is based on cytosine-phosphodiester-guanine oligodeoxynucleotide (CpG ODN)-capped hollow mesoporous silica (HMS) particles as carriers. Fluorescein dye was used as a model drug, and the fluorescein loading, amino-grafting and CpG ODN capping were evaluated by UV/Vis analysis, zeta potential and N(2) adsorption-desorption measurements and gel electrophoresis. The fluorescein loading capacity and CpG ODN capping amount were 37.7 and 39.6 μg mg(-1), respectively at the weight ratio of 10 Dye/HMS-NH(2)/CpG ODN. Importantly, fluorescein release can be triggered by the addition of deoxyribonuclease I (DNase I) for CpG ODN degradation, and the release rate can also be controlled by changing the DNase I concentration. Therefore, it might be a promising controlled drug delivery system for application in the field of biomedicine and cancer therapy.     

Determination of cefquinome in pig plasma and bronchoalveolar lavage fluid by high-performance liquid chromatography combined with electrospray ionization mass spectrometry

The aim of this study was to develop a rapid and sensitive method for the quantification of cefquinome in animal plasma and bronchoalveolar lavage (BAL) fluid using high-performance liquid chromatography combined with electrospray tandem mass spectrometry (LC-ESI-MS/MS). Cefadroxil is used as internal standard. For plasma, the sample preparation includes a simple deproteinization step with a Microcon filter. This allows detecting the unbound cefquinome concentration, which is correlated with the concentration in other body fluids, such as BAL fluid. To be able to detect the total plasma concentration, deproteinization with acetonitrile, followed by a back-extraction of actonitrile with dichloromethane was performed. The BAL fluid is centrifuged to precipitate floating particles. Chromatographic separation is achieved on a PLRP-S column using 0.005% formic acid and methanol as mobile phase. For plasma, good linearity was observed in the range of 5-2500 ng ml(-1) for both the unbound and total concentration. The response in BAL fluid was linear in the range of 4-1000 ng ml(-1). The limit of quantification (LOQ) was set at 5.00 ng ml(-1) for plasma and at 4.00 ng ml(-1) for BAL fluid. The limit of detection (LOD) was 3.12 ng ml(-1) and 0.41 ng ml(-1) for the unbound and total concentration in plasma, respectively, and was 1.43 ng ml(-1) for BAL fluid. The method was shown to be of use in a pharmacokinetic study in pigs, where the correlation between cefquinome concentrations in plasma and BAL fluid of pigs was studied.     

Determination of an irreversible inhibitor of monoamine oxidase B (MDL 72974A) in human plasma and urine by gas chromatography-positive-ion chemical ionization mass spectrometry.

A sensitive and specific assay has been developed for the quantitative measurement in human plasma and urine of the irreversible inhibitor of monoamine oxidase B [(E)-4-fluoro-beta-fluoromethylenebenzene-butanamine HCl salt] (MDL 72974A) (I). This assay is based on gas chromatography-mass spectrometry with ammonia as the chemical ionization reagent gas. After addition of 1-fluoro-2-(4-chlorobenzene)-ethanamine HCl salt (MDL 71946A) as the internal standard, plasma (1 ml) and urine (100 microliter) samples were extracted using an automated solid-liquid extraction procedure on CN columns. The eluent was dried with a stream of nitrogen, and the residue was derivatized with pentafluoropropionic anhydride. Selected-ion monitoring of the [MNH4]+ ions m/z 361 (I) and 351 (internal standard) was used for quantification. The method yielded a linear response over the concentration range 0.25-100 pmol/ml in plasma with a limit of quantitation of 0.25 pmol/ml. The within-day reproducibility at a concentration of 5 pmol/ml was 4.6% and at a concentration of 50 pmol/ml was 1.3%. The day-to-day reproducibility was 5.2 and 7.0% at concentrations of 10 and 30 pmol/ml, respectively. The method was applied to the quantification of I in plasma and urine after the administration of 12-mg doses of I to a healthy male volunteer.     

Simultaneous analysis of twenty-one glucocorticoids in equine plasma by liquid chromatography/tandem mass spectrometry

A method for the simultaneous separation, identification, quantification and confirmation of the presence of 21 glucocorticoids (GCC) in equine plasma by liquid chromatography coupled with triple stage quadrupole tandem mass spectrometry (LC/TSQ-MS/MS) is described. Plasma sample augmented with the 21 GCC was extracted with methyl tert-butyl ether (MTBE) and analyzed by positive electrospray ionization. Desoxymetasone or dichlorisone acetate was used as the internal standard (IS). Quantification was performed by IS calibration. For each drug, one major product ion was chosen and used for screening for that drug. Analyte confirmation was performed by using the three most intense product ions formed from the precursor ion and the corresponding mass ratios. The recovery of the 21 GCC when spiked into blank plasma at 5 ng/mL was 45-200% with coefficient of variation (CV) from 0.3-18%. The limit of detection (LOD) and that of quantification (LOQ) for most of the analytes were 50-100 pg/mL and 1 ng/mL, respectively, whereas that of confirmation (LOC) was 100-300 pg/mL depending on the analyte. Intra- and inter-day precisions expressed as CV for quantification of 1 and 10 ng/mL was 1.0-17%, and 0.51-19%, respectively, and the accuracy was from 84-110%. The linear concentration range for quantification was 0.1-100 ng/mL (r(2) > 0.997). Estimated measurement uncertainty was from 11-37%. This study was undertaken to develop a method for simultaneous screening, identification, quantification and confirmation of these agents in post-race equine plasma samples. The method has been successfully applied to screening of a large number of plasma samples obtained from racehorses in competition and in pharmacokinetic studies of dexamethasone in the horse and concurrent changes in endogenous GCC, hydrocortisone and cortisone. The method is simple, sensitive, selective and reliably reproducible.     

Electrochemical biosensors for detection of point mutation based on surface ligation reaction and oligonucleotides modified gold nanoparticles

An electrochemical method for point mutation detection based on surface ligation reaction and oligonucleotides (ODNs) modified gold nanoparticles (AuNPs) was demonstrated. Point mutation identification was achieved using Escherichia coli DNA ligase. This system for point mutation detection relied on a sandwich assay comprising capture ODN immobilized on Au electrodes, target ODN and ligation ODN. Because of the sequence-specific surface reactions of E. coli DNA ligase, the ligation ODN covalently linked to the capture ODN only in the presence of a perfectly complementary target ODN. The presence of ligation products on Au electrode was detected using chronocoulometry through hybridization with reporter ODN modified AuNPs. The use of AuNPs improved the sensitivity of chronocoulometry in this approach, a detection limit of 0.9 pM complementary ODN was obtained. For single base mismatched ODN (smODN), a negligible signal was observed. Even if the concentration ratio of complementary ODN to smODN was decreased to 1:1000, a detectable signal was observed. This work may provide a specific, sensitive and cost-efficient approach for point mutant detection.     

Anidulafungin—challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies

Anidulafungin is a semi-synthetic echinocandin with antifungal activity, usually administered as an intravenous infusion. In order to determine the pharmacokinetics (PK) of anidulafungin in pediatric patients, a sensitive high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) bioanalytical method (M1) was developed and validated for quantification of anidulafungin in plasma. During analysis of incurred samples (samples collected from patients enrolled in a clinical study) an isobaric chromatographic interference was observed. The source of interference was identified as an anidulafungin open-ring form (D1) and its impact on the quantification of anidulafungin was investigated. It was found that accurately quantifying anidulafungin in incurred samples required chromatographic separation of the open-ring form from anidulafungin. The method was redeveloped to achieve the appropriate baseline separation and to avoid experimental conditions that favored opening the anidulafungin ring. The extraction of anidulafungin from plasma by protein precipitation remained unchanged, but the changes in chromatography warranted validation of a new method, M2, 2?years after M1 was validated. Incurred samples from three studies that were previously analyzed by M1 and were within confirmed long-term frozen stability were then reanalyzed by M2. Although the incurred sample reproducibility tests on those samples passed for each of the two methods, comparison of concentrations from the same samples obtained by M1 and M2 revealed that an overestimation of anidulafungin following the M1 method exceeded acceptance criteria. The new HPLC-MS/MS method (M2) is applicable for quantification of anidulafungin within a nominal range 50-20,000?ng/mL and requires a 50?μL human plasma aliquot. A linear, 1/concentration squared weighted, least-squares regression algorithm was used to generate the calibration curve and its parameters were used to quantitate the incurred samples. The inter-assay accuracy in heparin human plasma validation ranged from -4.33 to 0.0386?% and precision was ≤7.32?%. The method M2 was validated for use in regulated bioanalysis and is presently used to quantitate anidulafungin in plasma samples from clinical studies.